Information Provided By:
Fly News Breaks for November 13, 2019
Nov 13, 2019 | 06:25 EDT
BofA/Merrill analyst Jason Gerberry initiated coverage of Arena Pharmaceuticals with a Neutral rating and $51 price target. The analyst believes the company has a potentially best-in-class oral immune-modulator, but he sees a lack of catalysts for its key irritable bowel disease program.
News For ARNA From the Last 2 Days
There are no results for your query ARNA